A Single-centre, Before-After Study of the Short- and Long-term Efficacy of Narivent® in the Treatment of Nasal Congestion

Objective: Nasal congestion is a common symptom in allergic and nonallergic rhinitis, rhinosinusitis and nasal polyposis. The present study evaluated the clinical effectiveness of Narivent®, an osmotically-acting medical device with anti -oedematous and anti-inflammatory effects, in nasal congestion...

Full description

Saved in:
Bibliographic Details
Published in:Journal of international medical research 2012-10, Vol.40 (5), p.1931-1941
Main Authors: Damiani, V, Camaioni, A, Viti, C, Scirè, As, Morpurgo, G, Gregori, D
Format: Article
Language:English
Subjects:
Administration, Intranasal
Adult
Anti-Inflammatory Agents - administration & dosage
Cyclohexanols - administration & dosage
Drug Combinations
Female
Glycyrrhizic Acid - administration & dosage
Humans
Hypertrophy - drug therapy
Male
Mannitol - administration & dosage
Middle Aged
Monoterpenes - administration & dosage
Nasal Obstruction - drug therapy
Treatment Outcome
Turbinates - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: Nasal congestion is a common symptom in allergic and nonallergic rhinitis, rhinosinusitis and nasal polyposis. The present study evaluated the clinical effectiveness of Narivent®, an osmotically-acting medical device with anti -oedematous and anti-inflammatory effects, in nasal congestion. Methods: A single-centre, prospective study with a pre- post design and consecutive patient enrolment was conducted in an Italian otolaryngology department. Patients with persistent nasal congestion were allocated to treatment groups as follows: group 1 (n = 36) treated for 7 days; group 2 (n = 56) treated for 30 days. In each group, patients received two puffs of Narivent® into each nostril twice daily. Symptom severity was assessed subjectively on a 0 - 10 visual analogue scale, and objectively by the presence/absence of signs and symptoms. Differences in subjective and objective severity measures before and after treatment were compared using Wilcoxon's signed rank test. Results: All symptoms and objective scores improved after treatment with Narivent® for 7 or 30 days and no adverse effects were reported by the patients in either group. Conclusion: Narivent® appears to be efficacious in treating nasal congestion over a 7- or a 30-day period.
ISSN:0300-0605
1473-2300
DOI:10.1177/030006051204000534